Subtype
Liver Carcinoma
CI-CAN-00001073Explore in graph →
783 active trials14 approved drugs17 evidence items
- NCIt
- C7927
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001073Explore in graph →
Clinical trials
3,367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (386)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00823290 | Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 | 2 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT02029690 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin(TRAP) | terminated | Phase 1 | 85 | Polaris GroupINDUSTRY | 2 | Sep 25, 2020 | clinicaltrials |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | terminated | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03480152 | Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2020 | clinicaltrials |
| NCT02013778 | Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC | terminated | Phase 1 / Phase 2 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT03382886 | Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma(NUANCE) | terminated | Phase 1 | 1 | University of UtahOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT03349255 | Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma | terminated | Phase 1 | 3 | Aeon Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Jul 1, 2019 | clinicaltrials |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis | terminated | Phase 1 / Phase 2 | 1 | Taiwan Liposome CompanyINDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT01425996 | A Dose-escalation Study of Lipotecan® Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 3 | Taiwan Liposome CompanyINDUSTRY | 1 | Aug 21, 2018 | clinicaltrials |
| NCT02690350 | An Open Study Assessing the Safety and Tolerability of U3-1784 | terminated | Phase 1 | 10 | Daiichi SankyoINDUSTRY | 1 | May 16, 2018 | clinicaltrials |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | terminated | Phase 1 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy | terminated | Phase 1 | 26 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) | terminated | Phase 1 | 33 | Korea Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 9, 2017 | clinicaltrials |
| NCT02323906 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | terminated | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Stanford UniversityOTHER | 1 | Jul 27, 2016 | clinicaltrials |
| NCT00971126 | Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 3 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT00669136 | Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma | terminated | Phase 1 | 2 | Lisa H. Butterfield, Ph.D.OTHER | 1 | Dec 3, 2015 | clinicaltrials |
| NCT01521780 | Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215) | terminated | Phase 1 | 12 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 2, 2015 | clinicaltrials |
| NCT01348503 | Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma | terminated | Phase 1 | 5 | Indiana UniversityOTHER | 1 | Aug 31, 2015 | clinicaltrials |
| NCT01029418 | AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT00081900 | A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care | terminated | Phase 1 / Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 13, 2015 | clinicaltrials |
| NCT01128803 | Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response | terminated | Phase 1 / Phase 2 | 1 | Nantes University HospitalOTHER | 1 | Nov 7, 2013 | clinicaltrials |
| NCT00862082 | Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 14 | Proacta, IncorporatedINDUSTRY | 4 | Aug 23, 2013 | clinicaltrials |
| NCT00828594 | Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma | terminated | Phase 1 | 130 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 11, 2013 | clinicaltrials |
| NCT00966251 | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 2 | CureTech LtdINDUSTRY | 1 | Oct 23, 2012 | clinicaltrials |
| NCT00426829 | Proton Therapy and Bevacizumab for Primary Liver Tumors | terminated | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2012 | clinicaltrials |
| NCT00562666 | Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells(ICAR) | terminated | Phase 1 | 2 | Rennes University HospitalOTHER | 1 | Jun 22, 2012 | clinicaltrials |
| NCT00791544 | Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma | terminated | Phase 1 / Phase 2 | 13 | SanofiINDUSTRY | 1 | Aug 4, 2010 | clinicaltrials |
| NCT00319683 | A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | — | Adherex Technologies, Inc.INDUSTRY | 3 | Dec 15, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Dec 14, 2020source: clinicaltrials